Back to results

CompletedPhase 2Phase 3

A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants

NCT02337738

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Nagoya, Aichi-ken, Japan

+56 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2015-01-27
Enrollment: 404 participants
Sponsor: Takeda
Purpose: treatment

Locations (57)

A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants — TrialFind